Summary Three biochemical markers of collagen metabolism were measured in 39 osteosarcoma patients.
We have previously shown that the amino-terminal propeptide of type III procollagen (PIIINP) is a prognostic factor in soft tissue sarcomas (Wiklund et al., 1992) . PIIINP was elevated particularly in the case of bone involvement of the tumour. Recently PIIINP has been shown to be both a prognostic factor and to reflect the clinical behaviour of multiple myeloma (Taube et al., 1992) . In this disease also the cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) is a prognostic factor, a measure of the extent of bone lesions and a sensitive marker of regression of the disease Abildgaard et al., 1994) . Both ICTP and the carboxy-terminal propeptide of type I procollagen, PICP, are elevated in prostate cancer with bone metastases (Kylmala et al., 1993 (Kylmala et al., , 1995 . Type I collagen is the major protein of mineralised bone, accounting for about 90% of its organic matrix, whereas type III collagen is an important matrix constituent of soft tissues, including the bone marrow and periosteum (Risteli and Risteli, 1989) . Thus, it seemed relevant to study these three metabolites, which measure synthesis (PIIINP, PICP) as well as degradation (ICTP) of collagen types I and III in osteosarcoma, a malignant primary bone tumour. Between 1986 and (Melkko et al., 1990; Risteli et al., 1988 Risteli et al., , 1993 . The reference intervals among healthy Finnish blood donors over 20 years of age are as follows: PIIINP 1.7-4.3figl-' (Risteli et al., 1988) , PICP 50-170igl-' for women and 40-200 fig 1-for men (Melkko et al., 1990) and ICTP 1.7-4.6 fig 1' . For patients less than 20 years old the upper limit of the reference range is higher, particularly for ICTP in young men (about 11 jig 1-l in men 16 -18 years old, and about 9jsgl-in men 18 -20 years old) (P Trivedi and J Risteli, unpublished data). The intra-and interassay coefficient of variation for the assays are around 5%.
Materials and methods

Patients
Statistical analysis
The changes in collagen metabolites within the patients were studied with the Wilcoxon signed-rank test. Correlations between the different metabolites, and between the metabolites and age were assessed by the Spearman's rank-order correlation coefficient (rj). The effect on different variables on survival was studied with the method of proportional hazards. In these analyses the log transformed values of the metabolites were used as continuous variables.
Results
Pretreatment values
The pretreatment concentrations of PIIINP, PICP and ICTP are shown in Table I . There is no difference between the concentrations obtained for those patients who later remained in continuous remission and those with a later relapse of the disease. For alkaline phosphatase (AP) and lactate ._. reference range within 5 years, and PIIINP within 8 months after the last chemotherapy infusion. The changes in PICP were at most a slight increase of short duration after the completion of the post-operative chemotherapy. , 1991) . There is however a need for intensified treatment in selected patients, and thus also for new sensitive and specific prognostic factors. Based on our experiences on soft tissue sarcomas and multiple myeloma as well as on prostate cancer metastatic to bone we had reasons to expect that metabolites of type I and III collagen could be of use in osteosarcoma Taube et al., 1992; Wiklund et al., 1992; Kylmala et al., 1993) .
The present study indicates that elevated concentrations of type I and III collagen metabolites, particularly ICTP and PIIINP, are frequent findings in untreated osteogenic sarcoma. On the other hand, the circulating concentrations of PICP, which as part of the type I procollagen is a characteristic gene product of the osteoblastic cells, was much less often increased, suggesting that the malignant cells are not more active in producing this protein than are the normal osteoblasts. AP is another product of the osteoblast, and considered to be expressed later than type I collagen in the phenotypic development of this cell (Stein et al., 1990) . It is interesting that this enzyme is a prognostic factor with respect to survival in osteosarcoma, a finding that was confirmed here, as also the prognostic implication of LD (Link et al., 1991; Bacci et al., 1993) .
We report two important findings here. Firstly, in contrast to previous studies on these metabolites in malignant disease our study population was made up almost exclusively of young persons. The majority of patients had initially elevated values of PIIINP and ICTP. It is probable that part of this elevation is a result of the young age of the patients (P Trivedi, unpublished data). Furthermore, the correlation between ICTP and age suggests this.
Secondly, this study confirms our previous findings on the effect of therapy per se on collagen metabolism (Haukipuro et al., 1990; Wiklund et al., 1993) . The intensive multimodality treatment of osteosarcoma clearly affect the collagen metabolism. In this study population the long diseasefree follow-up made it possible to analyse the time it takes for collagen metabolism to normalise. For ICTP the time is surprisingly long. However, although the pattern of decline was similar in patients above or below 20 years (data not shown) it should be emphasised that all patients except one were below 35 years of age at diagnosis, and thus the type I collagen metabolism could be expected to be more active than in an older age. Thirdly, these findings emphasise that clinical results from biochemical markers reflecting tissue destruction and repair, such as the three used here, must be interpreted with caution.
Time Figure 2 The changes in PIIINP (a), PICP (b) and ICTP (c) during the therapy and the follow-up. A, baseline value; B, preoperative value; C, post-operative value; D, value during last post-operative chemotherapy cycle; 1 month, values obtained 1 month after the last chemotherapy infusion, and thereafter monthly up to I year after the last chemotherapy cycle (= 1 year). From this point values are shown yearly until 10 years. Only measurements obtained during disease-free follow-up are included (i.e. from date of metastases all measurements are excluded). Bottom, individual graphs for each patient. Top, mean and 95% confidence intervals (at 7 months and 12 months after completion of therapy less than four measurements were available, these were excluded). . .
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